Antibacterial agents in pregnancy

Area of Science:

• Pharmacology
• Maternal-Fetal Medicine
• Infectious Diseases

Background:

• Antibiotic use in pregnancy necessitates balancing maternal health with potential fetal risks.
• Limited data exists on the safety of many antimicrobial agents for the developing fetus.
• Absolute safety ratings are not assigned to any antimicrobial during pregnancy.

Purpose of the Study:

• To review the safety profiles of various antimicrobial classes for use during pregnancy.
• To guide the selection of appropriate antibiotics for pregnant patients requiring treatment.
• To highlight drugs with established safety records and those to be used with caution.

Main Methods:

• Review of existing literature on antibiotic pharmacokinetics and safety in pregnant women.
• Analysis of data from animal studies and human observational studies.
• Evaluation of clinical experience with commonly used and newer antimicrobial agents.

Main Results:

• Penicillins, cephalosporins, and erythromycins demonstrate established safety and pharmacokinetic profiles in pregnancy.
• Aminoglycosides can be used with careful maternal serum level monitoring.
• Quinolones, sulfonamides, and tetracyclines carry risks and should be avoided unless maternal necessity outweighs fetal toxicity.
• Newer macrolides like azithromycin and clarithromycin have limited safety data.
• First-line tuberculosis drugs (isoniazid, rifampin, ethambutol) are generally safe, but alternatives may be needed for resistant strains.

Conclusions:

• Antibiotic selection in pregnancy must prioritize fetal safety, favoring well-documented agents.
• Risk-benefit assessment is crucial, especially when considering drugs with known or suspected fetal toxicity.
• Continued research is needed for newer agents, and careful monitoring is essential for others.